Albert Schweitzer Ziekenhuis — Clinical Trial Site

125 Registered trials

53 Currently recruiting

Organisation

Albert Schweitzer Ziekenhuis

Location

Dordrecht, Netherlands

Identifier

ORG-100042264

Address

Langeweg 336, 3331 LZ, Netherlands

Departments

-
#2153: Hematology
#2201: oncology
#2906:Internal Medicine
031006: Oncology
5002:Internal medicine
Afd. Interne geneeskunde
Afdeling Interne geneeskunde, Trials & Research
Afdeling Interne geneeskunde
ASZ Dordrecht dept. Internal medicine
Cardiologie
Cardiology
Clinical Pharmacy
Department Internal Medicine
Department of Hematology
Department of Internal Medicine
Department of Surgical Oncology
Diabatescentrum voor volwassenen (Diabetes center for adults)
Endocrinologie
Gastroenterology
Gynaecology
Hematologie
Hematology
Intensive Care
Internal Medicine
Internal Medicine - Hematology
Internal medicine - oncology
Internal Medicine / Oncology
Internal Medicine Department
Internal Medicine, Hemato-Oncology
Internal medicine, hematology
Internal Medicine, Vascular Medicine
Internal medicine/haematology
Internal Oncology
Interne geneeskunde
Interne geneeskunder
Longziekten
Maag-, Darm- en Leverziekten
MDL
Medical Oncology
N/A
NA
Nefrologie
Nephrology
Neurology
NL10003: Internal medicine
Obstetrics & Gynecology
Oncologie
Oncology
Ophthalmology
Rheumatology
Surgery

Clinical trials at this site (125)

Search interface

A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine in unfit… Ended

2023-503829-18-00 Acute myeloid leukemia 4 2019-12-05
Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio… Ended

2022-502832-37-00 Acute myeloid leukemia 5 2019-03-01
A Study of combination of Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) compared to VELCADE, Lenalidomide, and … Ended

2023-506125-10-00 Multiple Myeloma 5 2018-12-24
HOVON 151 DLBCL: A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diff… Ended

2022-501076-26-00 high risk diffuse large B-cell lymphoma 4 2018-08-28
Endocrine therapy plus CDK 4/6 inhibition in first- or second-line for hormone receptor positive advanced breast cancer - the SONIA study Ended

2024-516204-42-00 Breast cancer 5 2017-11-21
Sustained treatment-free period in the course of a disease when symptoms become less severe in BCR-ABL+ chronic myeloid leukemia: a prospect… Ended

2023-510434-83-00 Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) 6 2016-10-17
An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) Ended

2023-508606-26-00 Metastatic castration-resistant prostate cancer (mCRPC) 5 2015-04-23
Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumaB as first-lin… Ended

2024-516202-39-00 Metastatic breast cancer 4 2013-10-10
PUMP-IT RCT: Hepatic arterial infusion PUMP chemotherapy combined with systemic therapy versus systemic therapy alone as Induction Therapy f… Halted

2023-506194-35-00 Colorectal liver metastases 5 2024-11-21
Effects of NNC0194-0499, cagrilintide, and semaglutide alone or in combinations on liver damage and alcohol use in people with alcohol-relat… Ended

2023-508170-28-00 alcohol-related liver disease 4 2024-08-07
A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia Ended

2024-511331-96-00 Mixed Dyslipidemia 4 2024-07-04
A Study of the Efficacy, Safety, and Tolerability of KAN-101 in Participants With Celiac Disease Ended

2023-507240-37-00 celiac disease 4 2024-04-30
MLS-101-301: A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of … Ended

2023-506425-12-00 Uncontrolled and Resistant Hypertension 5 2024-04-17
A study to learn more about how well BAY 3018250 works and how safe it is for people with proximal deep vein thrombosis Ended

2023-503315-15-00 Thrombolysis of symptomatic proximal vein thrombosis 4 2023-12-20
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hype… Ended

2022-503022-13-00 Hypertriglyceridemia, Cardiovascular Diseases, Atherosc 5 2023-06-08
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Ended

2022-501420-20-00 Severe hypertryglyceridemia 5 2023-05-17
The effect of oral folinic acid to prevent pemetrexed induced adverse events. Ended

2022-502345-10-00 Non small cell lung cancer (NSCLC), Mesothelioma, Thymo 6 2023-02-05
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended

2023-503794-38-00 Prevention of stroke or systemic embolism in atrial fib 5 2022-11-24
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin … Ended

2024-513992-42-00 venous thromboembolism (VTE) in patients with gastroint 10 2022-09-13
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on… Ended

2023-509569-19-00 venous thromboembolism (VTE) 10 2022-08-10
A study to learn how well the treatment combination of finerenone and empagliflozin works and how safe it is compared to each treatment alon… Ended

2023-506981-30-00 Chronic kidney disease in type 2 diabetes mellitus 4 2022-05-25
A clinical study to investigate if the investigational drug Diamyd is safe and can preserve insulin production and secretion in adolescents … Ended

2024-513304-33-00 Type 1 diabetes mellitus 5 2022-03-17
A study designed to evaluate a modified Anti-Platelet Therapy (drugs that preventblood platelets from clotting) after implantation of a Fire… Ended

2024-519854-35-00 Acute Myocardial Infarction 6 2021-06-29
Treatment with Acalabrutinib in patients with chronic lymphocytic leukemia Ended

2023-507669-24-00 Chronic lymphocytic leukemia 5 2019-11-05